Stock BAVA BAVARIAN NORDIC A/S
Add to a list
To use this feature you must be a member
Log inSign up
PDF Report : Bavarian Nordic A/S

Bavarian Nordic A/S Stock price

Equities

BAVA

DK0015998017

Pharmaceuticals

Real-time Estimate Cboe Europe
Other stock markets
 03:50:58 2023-12-08 am EST 		Intraday chart for Bavarian Nordic A/S 5-day change 1st Jan Change
171.8 DKK +1.12% +4.81% -19.40%
Dec. 05 Stigma, regulatory barriers delay mpox response in country that needs it most RE
Nov. 20 Nordic Shares Closed Up Monday; Better Collective Topped Leaders DJ

Financials

Sales 2023 * 6.89B 997M Sales 2024 * 5.38B 778M Capitalization 13.24B 1.91B
Net income 2023 * 1.15B 167M Net income 2024 * 1.22B 177M EV / Sales 2023 *
1,63x
Net cash position 2023 * 1.99B 287M Net cash position 2024 * 2.63B 380M EV / Sales 2024 *
1,97x
P/E ratio 2023 *
11,3x
P/E ratio 2024 *
12,4x
Employees 1,351
Yield 2023 *
-
Yield 2024 *
-
Free-Float 99.7%
More Fundamentals * Assessed data

Chart Bavarian Nordic A/S

Dynamic Chart

Latest news about Bavarian Nordic A/S

Stigma, regulatory barriers delay mpox response in country that needs it most RE
Nordic Shares Closed Up Monday; Better Collective Topped Leaders DJ
Nordic Shares Closed Down Thursday; Better Collective Fell Furthest DJ
Transcript : Bavarian Nordic A/S, Q3 2023 Earnings Call, Nov 16, 2023 CI
Bavarian Nordic Confirms FY23 Revenue Growth Outlook MT
Bavarian Nordic A/S Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Bavarian Nordic A/S Provides Earnings Guidance for the Year 2023 CI
Bavarian Nordic Wins US Regulatory Nod for Mpox Vaccine in Adults MT
US CDC panel recommends Bavarian Nordic's vaccine for adults at risk of mpox RE
Bavarian Nordic A/S's Mpox Vaccine Receives Recommendation from U.S. CDC Advisory Committee for Routine Use in Adults at Risk CI
Nordic Shares Decreased Tuesday; Beijer Ref Series B Posted Biggest Loss DJ
Bavarian Nordic Receives EUR11 Million Smallpox Vaccine Contract MT
Bavarian Nordic A/S Wins Another Contract to Supply Smallpox Vaccines for EU Strategic Reserve CI
Bavarian Nordic Flags Lack of Commercial Opportunity from COVID-19 Booster Amid New Variants MT
Bavarian Nordic A/S Reports Additional Phase 3 Results and Provides Update on Development Program for its cVLP-Based COVID-19 Booster Vaccine Candidate, ABNCoV2 CI
More news

Analyst Recommendations on Bavarian Nordic A/S

TODAY'S ANALYST RECOMMENDATIONS : Abercrombie & Fitch, Best Buy, Fedex, Medtronic, Snowflake...
More recommendations

Press releases Bavarian Nordic A/S

Report of transactions of shares and related securities of Bavarian Nordic by persons holding managerial responsibilities and/or persons/companies closely associated with such GL
Report of transactions of shares and related securities of Bavarian Nordic by persons holding managerial responsibilities and/or persons/companies closely associated with such AQ
Capital Increase in Bavarian Nordic A/S as a Result of Employee Warrant Exercise GL
Bavarian Nordic to hold Capital Markets Days in February 2024 GL
Bavarian Nordic Announces Interim Results for the First Nine Months of 2023 GL
More press releases

News in other languages on Bavarian Nordic A/S

Les marchés rêvent d'un scénario ciel bleu
Bolsa de Madrid: Los mercados sueñan con un escenario de cielo azul
Le Nasdaq en perd son Alphabet
AVIS D'ANALYSTES DU JOUR : Worldline, Kering, Dassault Systèmes, GTT, Nexity, Straumann...
ÜBERBLICK/Anstehende Indexänderungen
More news

Quotes and Performance

1 day-1.39%
1 week+1.77%
Current month+1.77%
1 month+25.29%
3 months+20.84%
6 months-16.80%
Current year-20.38%
More quotes

Highs and lows

1 week
163.55
Extreme 163.55
173.20
1 month
135.75
Extreme 135.75
173.20
Current year
125.55
Extreme 125.55
256.00
1 year
125.55
Extreme 125.55
256.00
3 years
115.20
Extreme 115.2
411.00
5 years
103.20
Extreme 103.2
411.00
10 years
81.50
Extreme 81.5
444.00
More quotes

Managers and Directors - Bavarian Nordic A/S

Managers TitleAgeSince
Paul Chaplin CEO
 Chief Executive Officer 56 1998
Henrik Neilsen Juuel DFI
 Director of Finance/CFO 58 2018
Russell Thirsk COO
 Chief Operating Officer 55 2022
Members of the board TitleAgeSince
Anders Gersel Pedersen BRD
 Director/Board Member 72 2010
Frank Verwiel BRD
 Director/Board Member 60 2016
Peter Henrik Kürstein-Jensen BRD
 Director/Board Member 67 2012
More insiders

ETFs positioned on Bavarian Nordic A/S

Name Weight AuM 1st Jan change Investor Rating
DEKA STOXX EUROPE STRONG VALUE 20 UCITS ETF - EUR ETF Deka STOXX Europe Strong Value 20 UCITS ETF - EUR
2.81% 23 M€ +15.12%
DEKA STOXX EUROPE STRONG STYLE COMPOSITE 40 UCITS ETF - EUR ETF Deka STOXX Europe Strong Style Composite 40 UCITS ETF - EUR
1.47% 35 M€ +12.54%
XTRACKERS NORDIC NET ZERO PATHWAY PARIS ALIGNED UCITS ETF - EUR ETF Xtrackers Nordic Net Zero Pathway Paris Aligned UCITS ETF - EUR
0.96% 117 M€ 0.00%
More ETFs positioned on Bavarian Nordic A/S

Quotes

Date Price Change Volume
23-12-08 172.15 +1.32% 43 179
23-12-07 169.9 -1.39% 382,751
23-12-06 172.3 -0.35% 530,994
23-12-05 172.9 +4.60% 525,946
23-12-04 165.3 +0.73% 378,469

Delayed Quote Nasdaq Copenhagen, December 07, 2023 at 10:59 am EST

More quotes

Company Profile

Bavarian Nordic A/S specializes in the development, manufacturing and commercialization of cancer immunotherapies and vaccines for the prevention and treatment of infectious diseases. Net sales by revenue source are divided between sales of products (95.8%) and services (4.2%). Net sales are distributed geographically as follows: the United States (26.7%), Germany (20.6%), Belgium (10.6%), France (8.5%), Canada (6.3%), the United Kingdom (5.4%), Hong Kong (3.7%), Saudi Arabia (3.2%), Australia (3.1%), Switzerland (2.2%) and other (9.7%).
Sector
Pharmaceuticals
Calendar
2024-02-25 - Capital Market Day
More about the company

Income Statement Evolution

More financial data

Ratings for Bavarian Nordic A/S

Trading Rating :
Investor Rating :
ESG Refinitiv :
B
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
169.9DKK
Average target price
275.67DKK
Spread / Average Target
+62.25%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

1st Jan change Capi.
BAVARIAN NORDIC A/S Stock Bavarian Nordic A/S
-20.38% 1 917 M $
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+60.80% 529 B $
NOVO NORDISK A/S Stock Novo Nordisk A/S
+42.05% 430 B $
JOHNSON & JOHNSON Stock Johnson & Johnson
-12.03% 374 B $
MERCK & CO., INC. Stock Merck & Co., Inc.
-6.37% 263 B $
ABBVIE INC. Stock AbbVie Inc.
-8.44% 261 B $
ROCHE HOLDING AG Stock Roche Holding AG
-14.13% 229 B $
NOVARTIS AG Stock Novartis AG
+0.79% 198 B $
ASTRAZENECA PLC Stock AstraZeneca PLC
-9.98% 197 B $
PFIZER, INC. Stock Pfizer, Inc.
-44.13% 162 B $
Other Pharmaceuticals
  1. Stock
  2. Equities
  3. Stock Bavarian Nordic A/S - Nasdaq Copenhagen
The best tools reserved for subscribers to boost the performance of your investments!
Optimize my profits
fermer